Health News

A study published in the September 2010 issue of SHOCK by Dr. Ed W. Childs and colleagues at Scott & White Healthcare looks at how female versus male rats fared after suffering a trauma and subsequent hemorrhagic shock who were given Estradiol (estrogen). In the study, the Estradiol prevented vascular permeability following hemorrhagic shock.

Read more

Filed under: Pharmacy News
Tags: male, Pharmacy

Related posts

• Water pollution linked to male fertility problems (0)
  New research strengthens the link between water pollution and rising male fertility problems. Read more [tags] Pharmacy News [/tags]
  
  
• VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting (0)
  VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function. Read more [tags] Pharmacy News [/tags]
  
  
• VIVUS Initiates Open Label Safety Study Of Avanafil For Erectile Dysfunction (0)
  VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED). Read more [tags] Pharmacy News [/tags]
  
  
• Vigor-25 contains hidden drug ingredient, warns FDA (0)
  The U.S. Food and Drug Administration says Vigor-25, a product marketed as a natural dietary supplement to enhance male sexual performance, should not be purchased or used because it contains sildenafil, the active ingredient in the prescription drug Viagra. Read more [tags] Pharmacy News [/tags]
  
  
• Vantia Therapeutics’ Lead Candidate VA106483 Enters Phase IIb Trial For Nocturia (0)
  Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the [...]